
Sign up to save your podcasts
Or


The NHS approves a groundbreaking new “living drug” for aggressive leukaemia, offering fresh hope for patients whose cancer has returned or resisted treatment — and marking a major win for London’s life sciences sector.
Plus, UCL and Royal Free researchers push forward with greener, cheaper ways to manufacture next-gen cell therapies.
We also look at how UK scientists are repurposing Covid-era mRNA tech to protect against snake venom, and why new climate data shows Europe’s winters — including London’s — are becoming wetter far faster than models predicted.
Later in the episode, we speak to Prehistoric Planet: Ice Age executive producer Mike Gunton about snow sloths, Ice Age surprises, and the lessons ancient climate change still holds today.
Also in this episode:
For all the latest news, head to standard.co.uk.
Hosted on Acast. See acast.com/privacy for more information.
By The Evening Standard3.8
55 ratings
The NHS approves a groundbreaking new “living drug” for aggressive leukaemia, offering fresh hope for patients whose cancer has returned or resisted treatment — and marking a major win for London’s life sciences sector.
Plus, UCL and Royal Free researchers push forward with greener, cheaper ways to manufacture next-gen cell therapies.
We also look at how UK scientists are repurposing Covid-era mRNA tech to protect against snake venom, and why new climate data shows Europe’s winters — including London’s — are becoming wetter far faster than models predicted.
Later in the episode, we speak to Prehistoric Planet: Ice Age executive producer Mike Gunton about snow sloths, Ice Age surprises, and the lessons ancient climate change still holds today.
Also in this episode:
For all the latest news, head to standard.co.uk.
Hosted on Acast. See acast.com/privacy for more information.

611 Listeners

1,643 Listeners

968 Listeners

420 Listeners

416 Listeners

246 Listeners

401 Listeners

352 Listeners

352 Listeners

90 Listeners

476 Listeners

670 Listeners

224 Listeners

1 Listeners

20 Listeners

112 Listeners

0 Listeners

140 Listeners

0 Listeners

8 Listeners

2 Listeners

3 Listeners